Sigma Tau Pharma has announced the submission of an application to the European Medicines Agency (EMA) for use of its...
Baxter International Inc.announced it has signed a definitive agreement to acquire the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A....
Baxalta announced that the European Commission has granted Marketing Authorization for use of Oncaspar (pegaspargase) as a combination therapy in...
The CHMP recommended granting a marketing authorisation for Oncaspar (pegaspargase), from Medac, for the treatment of acute lymphoblastic leukaemia. It...
Shire plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
Shire PLC has announced that the FDA has accepted the Biologics License Application (BLA) for calaspargase pegol (Cal-PEG; SHP663). The...
A still major question in the field of acute lymphoblastic leukemia (ALL) in children - an extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the adolescents - is the optimal use of L-asparaginase (ASNase).
Pegaspargase (Oncaspar®), a pegylated form of native Escherichia coli-derived L-asparaginase (hereafter referred as E. coliL-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL)...